Insulet Corporation (NASDAQ: PODD) to Ring The NASDAQ Stock Market Closing Bell


ADVISORY, July 29, 2014 (GLOBE NEWSWIRE) --

What:

Insulet Corporation (Nasdaq:PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, will visit the NASDAQ MarketSite in Times Square.

In honor of the occasion, Duane DeSisto, Chief Executive Officer will ring the Closing Bell. 

Where:

NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Wednesday, July 30, 2014 – 3:45 p.m. to 4:00 p.m. ET  

Insulet Corporation Contact:
Jamie Aframe
(781) 457-4808
jaframe@insulet.com

NASDAQ MarketSite:
Christine Barna
(646) 441-5310
Christine.Barna@nasdaqomx.com

Feed Information:
Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq.

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx.

For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/.

Webcast:

A webcast of the NASDAQ Closing Bell will be available at:  https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx.

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About Insulet Corporation (Nasdaq:PODD):

Insulet Corporation is an innovative medical device company based in Bedford, Massachusetts. It was founded in 2000 with the mission of improving the lives of people with diabetes. Specifically, through its revolutionary OmniPod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy.

Studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (MDI); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. Despite these benefits, most people still choose MDI therapy largely due to the complexity, cost and inconvenience of conventional pump technology.

The OmniPod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. Improvements include OmniPod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. By breaking down the barriers to insulin pump therapy, Insulet hopes to provide both a superior treatment option and life-long health benefits for people with diabetes.

About NASDAQ OMX Group

NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,400 listed companies with a market value of over $8.5 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.

-NDAQA-